Detecting and tracking β-amyloid oligomeric forms and dynamics in vitro by a high-sensitivity fluorescent-based assay

Yanyan Zhao, Oleksandr Brener, Ewa Andrzejewska, Jiapeng Wei, CloudOuterMan Reiß, Ole Tietz, Tuomas P. J. Knowles, Franklin I. Aigbirhio*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Aggregation of β-amyloid protein is a hallmark pathology of the neurodegenerative disorder Alzheimer’s disease and proceeds from monomers to insoluble misfolded fibril forms via soluble and highly toxic oligomeric intermediates. Given the dual feature of being the most toxic form of the Aβ aggregate proteome and an early marker of pathogenesis, there is a need for sensitive methods that can be used to detect Aβ oligomers and investigate the dynamics of aggregation. Herein, we describe a method based on the application of an oligomer-sensitive fluorescent chemical probe pTP-TFE combined with the use of a QIAD (Quantitative determination of Interference with Aβ Aggregate Size Distribution) assay to correctly identify Aβ oligomers in high sensitivity. pTP-TFE was evaluated and compared to thioflavin T and pFTAA, the two most widely used amyloid fibril dyes, and shown to be the only probe capable of detecting significant differences across all oligomeric species of β-amyloid. Furthermore, by observing changes in pTP-TFE fluorescence emission over time, we could track the dynamics of oligomer populations and thereby obtain kinetic information on the Aβ42 dynamic aggregation model. Therefore, we have established a highly sensitive, readily available, and simple method for studying β-amyloid protein aggregation dynamics.
Original languageEnglish
Pages (from-to)4383-4389
Number of pages7
JournalACS Chemical Neuroscience
Volume15
Issue number24
Early online date2 Dec 2024
DOIs
Publication statusPublished - 18 Dec 2024

Bibliographical note

Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • amyloid oligomers
  • fluorescent probes
  • oligomer dissociation kinetics
  • Alzheimer’s disease
  • medicinal chemistry
  • neurological agents

Cite this